ARS Pharmaceuticals Inc. Company Profile
NASDAQ: SPRYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 4.59 +0.65%
ARS Pharmaceuticals at a glance
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in San Diego, CA. ARS Pharmaceuticals is led by Mr. Donn Casale and employs about 195 people. The company's shares have traded publicly since 2020.
At a market capitalization of $453.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001671858, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does ARS Pharmaceuticals do?
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- ARS Pharmaceuticals Inc.
- Ticker
- NASDAQ: SPRY
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Donn Casale
- Employees
- 195
- Headquarters
- 11682 El Camino Real, San Diego, CA, United States
- Phone
- 858 771 9307
- Website
- ars-pharma.com
- IPO year
- 2020
- Market cap
- $453.48M
- SEC CIK
- 0001671858
- Latest annual report
- 10-K · Mar 9, 2026
Companies similar to ARS Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OVIDOvid Therapeutics Inc. | 2.34 | -0.85% | $457.00M | vs SPRY |
| RZLTRezolute Inc. | 4.64 | +5.94% | $448.79M | vs SPRY |
| KMDAKamada Ltd. | 7.78 | -1.46% | $448.70M | vs SPRY |
| ASMBAssembly Biosciences Inc. | 22.82 | -0.57% | $464.63M | vs SPRY |
| PRTAProthena Corporation plc | 8.61 | +1.53% | $442.01M | vs SPRY |
| CAPRCapricor Therapeutics Inc. | 8.01 | -1.11% | $465.69M | vs SPRY |
| DMACDiaMedica Therapeutics Inc. | 8.01 | +0.25% | $431.94M | vs SPRY |
| ARVNArvinas Inc. | 7.51 | +0.81% | $484.55M | vs SPRY |